Company: TLSA
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001013762-25-001691
Chunk: 13

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 13
---
 regulatory 
 approval for or commercialize our product candidates.                                                                                    |

| ● | Our rights to develop and                                                                                                              
 commercialize our product candidates are subject to the terms and conditions of licenses granted to us by others. If we fail to comply 
 with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights 
 that are important to the business.                                                                                                    |

<div align='center'>-4-</div>

| ● | If our competitors are                                                                                                                      
 able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates, 
 we may not be able to have competing products approved by applicable regulatory authorities for a significant period of time. In            
 addition, even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect us from competition.          |

| ● | Healthcare legislative                                                                
 reform measures may have a negative impact on our business and results of operations. |

| ● | Our common shares may be                                                                       
 delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards. |

| ● | Because we are a foreign                                                              
 corporation, you may not have the same rights as a shareholder in a U.S. corporation. |

| ● | Claims of U.S. civil liabilities   
 may not be enforceable against us. |

| ● | If we are a passive foreign                                                                      
 investment company, there could be adverse U.S. federal income tax consequences to U.S. holders. |

Corporate Information We were originally incorporated under the laws of England and Wales on February 11, 1998 with the goal of leveraging the expertise of our management team as well as Dr. Napoleone Ferrara, Dr. Arun Sanyal, Dr. Howard Weiner and Dr. Kevan Herold, and to acquire and exploit certain intellectual property in biotechnology. We subsequently changed our name to Tiziana Life Sciences plc in April 2014 as a result of the acquisition of Tiziana Pharma Limited in April 2014. On August 20, 2021 we announced that we had formally commenced a strategic plan to change our corporate structure by establishing Tiziana Life Sciences Ltd, a Bermuda-incorporated company, to become the ultimate parent company of the Tiziana Group. The reorganization was performed under a scheme of arrangement under Part 26 of the UK Companies Act 2006 and became effective on October 20, 2021, at which point